Changes in Amer Sports structure and leadership team
/
Date29 Nov 2016
Amer Sports Corporation STOCK EXCHANGE RELEASENovember 29, 2016 at 9:00 a.m. Changes in Amer Sports structure and leadership team In line with Amer Sports strategy to... Read More →
Pacific Prime signs partnership agreement with Bahrain-based broker Protection Insurance Services
/
Date29 Nov 2016
HONG KONG, Nov. 29, 2016 (GLOBE NEWSWIRE) — via PRWEB – Pacific Prime, a leading global insurance advisor, is proud to announce a new strategic... Read More →
Nivalis Therapeutics Announces Results from Phase 2 Clinical Trial of Cavosonstat for Treatment of Cystic Fibrosis
/
Date28 Nov 2016
BOULDER, Colo., Nov. 28, 2016 (GLOBE NEWSWIRE) — Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on treating people with cystic fibrosis (“CF”),... Read More →
Eyenovia, Inc. announces publication of Phase II study results demonstrating benefits of micro-formulation over conventional eyedroppers and addition of Scientific Advisory Board members
/
Date28 Nov 2016
Eyenovia’s study shows that conventional ophthalmic eye drops significantly overdose the eye and that equivalent, or greater, pharmacodynamic effect can be achieved with 80% less... Read More →
Recro Pharma Reports Positive Top-Line Results from Pivotal Phase III Clinical Trial of IV Meloxicam
/
Date28 Nov 2016
IV Meloxicam Achieves Primary Endpoint of Statistically Significant Reduction in SPID24 in Patients with Acute Postoperative Pain Following Abdominoplasty Surgery Ten Secondary Endpoints Also Met... Read More →
Novo Nordisk A/S – aktietilbagekøbsprogram
/
Date28 Nov 2016
Bagsværd, 2016-11-28 – Den 28. oktober 2016 iværksatte Novo Nordisk et aktietilbagekøbsprogram i overensstemmelse med artikel 5 i Europa-Parlamentet og Rådets forordning (EU) nr. 596/2014... Read More →
Novo Nordisk A/S – Share repurchase programme
/
Date28 Nov 2016
Bagsværd, Denmark, 28 November 2016 – On 28 October 2016, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No.... Read More →
Alder BioPharmaceuticals Initiates PROMISE 2 Pivotal Trial of Eptinezumab for the Prevention of Migraine
/
Date28 Nov 2016
BOTHELL, Wash., Nov. 28, 2016 (GLOBE NEWSWIRE) — Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced the initiation of... Read More →
Z-Medica to Present at Piper Jaffray Healthcare Conference
/
Date28 Nov 2016
WALLINGFORD, Conn., Nov. 28, 2016 (GLOBE NEWSWIRE) — via PRWEB — Z-Medica, LLC, a leading developer and marketer of hemostatic devices, announces today that President... Read More →
BioCorRx Selects Covance for Non-Clinical Studies, Announces the Addition of Dr. Bal S. Brar to its Drug Development Team, Plans Pre-IND Meeting with FDA
/
Date28 Nov 2016
ANAHEIM, CA, Nov. 28, 2016 (GLOBE NEWSWIRE) — BioCorRx Inc. (OTC PINK: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of alcohol and... Read More →